| Page 1951 | Kisaco Research
 

Dr Bijal Shah

MD Medical Oncology
Moffitt Cancer Center

Dr Bijal Shah

MD Medical Oncology
Moffitt Cancer Center

Dr Bijal Shah

MD Medical Oncology
Moffitt Cancer Center
 

Matthew Hewitt

Principal Scientist/Director - Tumor Microenvironment
Bellicum Pharmaceuticals

Matthew Hewitt

Principal Scientist/Director - Tumor Microenvironment
Bellicum Pharmaceuticals

Matthew Hewitt

Principal Scientist/Director - Tumor Microenvironment
Bellicum Pharmaceuticals
 

Jason Fierings

Distinguished Technical Staff
Draper Lab

Jason Fierings

Distinguished Technical Staff
Draper Lab

Jason Fierings

Distinguished Technical Staff
Draper Lab
 

Blythe Sather

Associate Director
Juno Therapeutics

Blythe Sather

Associate Director
Juno Therapeutics

Blythe Sather

Associate Director
Juno Therapeutics
 

Robert Tighe

Vice President, Research
TCR2 Therapeutics

Robert Tighe

Vice President, Research
TCR2 Therapeutics

Robert Tighe

Vice President, Research
TCR2 Therapeutics
 

Neil Sheppard

Head External Co-operations & Early Development Leader
GSK

Neil Sheppard

Head External Co-operations & Early Development Leader
GSK

Neil Sheppard

Head External Co-operations & Early Development Leader
GSK
 

Joern-Peter Halle

Senior Vice President, Head Translational Innovation Platform Immuno-Oncology and Head External Innovation
Merck KGaA

Peter is leading the Translational Innovation Platform Immuno-Oncology with global responsibility for the research, discovery, and translational aspects of Merck KGaA’s IO portfolio. As the global head for External Innovation he oversees the search & evaluation of external opportunities in all therapeutic areas ranging from academic collaborations to clinical assets. He is also responsible for innovation initiatives of the healthcare business and a member of the investment committee of Merck Venture, Merck KGaA’s corporate VC.

Joern-Peter Halle

Senior Vice President, Head Translational Innovation Platform Immuno-Oncology and Head External Innovation
Merck KGaA

Joern-Peter Halle

Senior Vice President, Head Translational Innovation Platform Immuno-Oncology and Head External Innovation
Merck KGaA

Peter is leading the Translational Innovation Platform Immuno-Oncology with global responsibility for the research, discovery, and translational aspects of Merck KGaA’s IO portfolio. As the global head for External Innovation he oversees the search & evaluation of external opportunities in all therapeutic areas ranging from academic collaborations to clinical assets. He is also responsible for innovation initiatives of the healthcare business and a member of the investment committee of Merck Venture, Merck KGaA’s corporate VC. He started his carrier in Merck KGaA 12 years ago as a member of the corporate development. Prior to joining Merck KGaA, he co-founded a biotech company focusing on R&D in dermatology where he was responsible for IP, bioinformatics, and technology development and served as a Chief Business Officer.

 

Laurence Cooper

Chief Executive Officer
Ziopharm

Laurence Cooper

Chief Executive Officer
Ziopharm

Laurence Cooper

Chief Executive Officer
Ziopharm
 

Michael Poisel

Penn Center for Innovation

Michael Poisel

Penn Center for Innovation

Michael Poisel

Penn Center for Innovation
 

Gary Sclar

Dana Farber Innovations

Gary Sclar

Dana Farber Innovations

Gary Sclar

Dana Farber Innovations